COVID-19: Mayo Clinic is committed to taking care of our patients, learners and staff. Learn more about guidelines for the resumption of live
(in-person) courses and conferences
effective July 1, 2021 and available COVID-19 online education and resources.
Akcea Therapeutics - Exhibitor


Company Website
 

Contact information

Trent Miller
tmiller@akceatx.com
(952) 300-5156

 

Virtual Exhibit Hall Home


Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, is a biopharmaceutical company headquartered in Boston, Massachusetts focused on developing and commercializing medicines to treat patients with serious and rare diseases. Akcea is commercializing TEGSEDI® (inotersen) in the U.S., E.U., Canada and Brazil, and WAYLIVRA® (volanesorsen) in the E.U., as well as advancing a mature pipeline of novel medicines, pelacarsen (AKCEA-APO(a)-LRx), vupanorsen (AKCEA-ANGPTL3-LRx), AKCEA-APOCIII-LRx, and AKCEA-TTR-LRx, with the potential to treat multiple diseases. All six drugs were discovered by Ionis, a leader in antisense therapeutics, and are based on Ionis’ proprietary antisense technology.

Additional Information:
Tegsedi Patient Consideration Brochure
Package Insert